Calamos Advisors LLC Increases Stock Position in Elevance Health, Inc. (NYSE:ELV)

Calamos Advisors LLC grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,774 shares of the company’s stock after purchasing an additional 131 shares during the period. Calamos Advisors LLC’s holdings in Elevance Health were worth $9,139,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Raelipskie Partnership bought a new position in Elevance Health during the 3rd quarter valued at about $26,000. PSI Advisors LLC purchased a new position in shares of Elevance Health during the third quarter valued at approximately $27,000. Eastern Bank bought a new position in shares of Elevance Health during the third quarter valued at approximately $31,000. Crews Bank & Trust purchased a new stake in shares of Elevance Health in the fourth quarter worth approximately $34,000. Finally, Dunhill Financial LLC lifted its stake in shares of Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after acquiring an additional 26 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Down 0.7 %

Shares of NYSE ELV opened at $402.29 on Wednesday. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The business has a fifty day moving average price of $386.45 and a 200 day moving average price of $456.00. The stock has a market capitalization of $93.30 billion, a P/E ratio of 15.71, a price-to-earnings-growth ratio of 1.19 and a beta of 0.83. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Equities research analysts expect that Elevance Health, Inc. will post 34.07 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be given a dividend of $1.71 per share. The ex-dividend date of this dividend is Monday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.70%. Elevance Health’s dividend payout ratio is presently 25.46%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ELV shares. StockNews.com raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Tuesday. Wells Fargo & Company cut their price target on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. UBS Group decreased their price objective on shares of Elevance Health from $605.00 to $555.00 and set a “buy” rating for the company in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $485.00 target price on shares of Elevance Health in a research note on Friday, January 24th. Finally, Barclays lifted their price target on shares of Elevance Health from $501.00 to $512.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $517.03.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.